\-\ Texto\\:\\ \ \(0\)\
\-\ vitals\\:\\ pulse\\ ox\\ w\\/\\ desats\\ to\\ mid\\-80s\\ w\\/\\ exertion\\;\\ heent\\:\\ multiple\\ facial\\ angiofibromas\\,\\ gingival\\ fibromas\\,\\ multiple\\ hypomelanotic\\ macules\\,\\ no\\ lad\\;\\ cv\\:\\ rrr\\;\\ lungs\\:\\ ctab\\ but\\ diminished\\ breath\\ sounds\\ bilaterally\\;\\ skin\\:\\ confetti\\ lesions\\ x4\\ extremities\\;\\ shagreen\\â\\€\\™s\\ patch\\ on\\ back\\,\\ subungual\\ fibromas\ \(0\)\
\-\ she\\ will\\ follow\\ up\\ w\\/\\ her\\ pulmonologist\\ every\\ 6\\ months\\ w\\/\\ pfts\\ and\\ ct\\ to\\ monitor\\ progression\\ of\\ her\\ pulmonary\\ disease\\;\\ there\\ is\\ currently\\ no\\ treatment\\ for\\ her\\ disease\\ aside\\ from\\ symptomatic\\ relief\\.\\ hormone\\ replacement\\ and\\ manipulation\\ with\\ progesterone\\ and\\ luteinizing\\ hormone\\ analogs\\ with\\ or\\ without\\ oophorectomy\\ have\\ been\\ tried\\ but\\ without\\ demonstrated\\ efficacy\\.\\ lung\\ transplantation\\ may\\ also\\ be\\ considered\\ as\\ pulmonary\\ involvement\\ of\\ ts\\ usually\\ carries\\ a\\ poor\\ prognosis\\,\\ with\\ progressive\\ disease\\ and\\ death\\ secondary\\ to\\ respiratory\\ insufficiency\\ within\\ 5\\ years\\.\ \(0\)\
\-\ cxr\\:\\ left\\ and\\ probable\\ r\\ lung\\ surgery\\ w\\/\\ hyperinflation\\ and\\ scattered\\ bilateral\\ increased\\ lung\\ markings\\ c\\/w\\ lymphangioleiomyomatosis\\;\\ no\\ definite\\ evidence\\ of\\ pneumothorax\\.\\ \\ \ \(0\)\
\-\ ct\\ \\(chest\\)\\:\\ severe\\ cystic\\ changes\\ in\\ lungs\\ w\\/\\ no\\ evidence\\ of\\ ptx\\ or\\ effusion\\.\\ \ \(0\)\
\-\ prior\\ ct\\ \\(abd\\,\\ pelvis\\)\\:\\ numerous\\ bilateral\\ fatty\\ lesions\\ w\\/in\\ kidneys\\ c\\/w\\ angiomyolipoma\\;\\ multiple\\ nonfatty\\ angiomyolipomas\\ bilaterally\\;\\ enlarged\\ lymph\\ node\\ in\\ l\\ iliac\\ chain\\;\\ cystic\\ structure\\ adjacent\\ to\\ the\\ uterus\\ on\\ l\\,\\ which\\ may\\ represent\\ a\\ retroperitoneal\\ lymphangioma\\ vs\\ an\\ enlarged\\ l\\ ovary\\ w\\/\\ cyst\\;\\ inhomogenous\\ enhancement\\ of\\ the\\ uterus\\ which\\ is\\ also\\ enlarged\\ c\\/w\\ fibroids\\;\\ multiple\\ osteoblastic\\ foci\\ w\\/in\\ the\\ vertebral\\ bodies\\ \\â\\€\\“\\ study\\ unavailable\ \(0\)\
\-\ prior\\ mri\\:\\ periventricular\\ calcifications\\ \\â\\€\\“\\ study\\ unavailable\ \(0\)\
\-\ tuberous\\ sclerosis\\ w\\/\\ pulmonary\\ lymphangioleiomyomatosis\\ \\(lam\\)\ \(0\)\
\-\ pulmonary\\ lymphangioleiomyomatosis\\ \\(lam\\)\\;\\ phakomatoses\\ \\(neurocutaneous\\ syndromes\\)\\ including\\ tuberous\\ sclerosis\\,\\ neurofibromatosis\\,\\ sturge\\ weber\\ disease\\,\\ von\\ hippel\\-lindau\\ syndrome\\,\\ and\\ ataxia\\ telangiectasia\\;\\ emphysema\\,\\ langerhans\\â\\€\\™\\ cell\\ histiocytosis\\ \\(eosinophilic\\ granuloma\\)\\;\\ lymphangioleiomyomatosis\\;\\ interstitial\\ pulmonary\\ fibrosis\\;\\ sarcoidosis\\;\\ pulmonary\\ lymphangiectasis\\;\\ diffuse\\ pulmonary\\ lymphangiomatosis\\,\\ lymphangiomas\\;\\ uterine\\ leiomyosarcoma\\ w\\/\\ lung\\ mets\\;\\ benign\\ metastasizing\\ uterine\\ leiomyomata\\;\\ mesenchymal\\ cystic\\ hamartoma\\ of\\ the\\ lung\\;\\ multiple\\ pulmonary\\ fibroleiomyomatosis\\ hamartomas\\ \\(very\\ rare\\)\ \(0\)\
\-\ 36\\ y\\/o\\ female\\ w\\/\\ a\\ history\\ of\\ complex\\ partial\\ seizures\\ since\\ childhood\\ and\\ two\\ episodes\\ of\\ spontaneous\\ pneumothorax\\ in\\ the\\ last\\ year\\ treated\\ w\\/\\ drainage\\ pleurodesis\\/\\ pleurectomy\\ reports\\ continued\\ dyspnea\\ on\\ exertion\\.\\ she\\ currently\\ takes\\ no\\ medications\\ and\\ has\\ no\\ family\\ history\\ of\\ any\\ problems\\.\ \(0\)\
\-\ tuberous\\ sclerosis\\ is\\ a\\ genetic\\ neurocutaneous\\ disorder\\ that\\ is\\ autosomal\\ dominant\\ in\\ the\\ one\\-third\\ of\\ familial\\ cases\\ or\\ either\\ due\\ to\\ spontaneous\\ mutation\\ or\\ mosaicism\\ in\\ non\\-familial\\ cases\\.\\ the\\ defect\\ is\\ in\\ the\\ tsc1\\ \\(chromosome\\ 9\\)\\ and\\ tsc2\\ \\(chromosome\\ 16p\\)\\ genes\\,\\ which\\ code\\ for\\ the\\ proteins\\ hamartin\\ and\\ tuberin\\ respectively\\,\\ although\\ the\\ functions\\ of\\ these\\ proteins\\ are\\ as\\ yet\\ unknown\\.\\ ts\\ manifests\\ with\\ multi\\-organ\\ involvement\\,\\ with\\ dermatologic\\ features\\ including\\ hypopigmented\\ lesions\\ \\(ash\\-leaf\\ spots\\)\\ and\\ connective\\ tissue\\ nevi\\ \\(shagreen\\ patch\\)\\,\\ and\\ cns\\ involvement\\ including\\ periventricular\\ calcifications\\ and\\ seizure\\ disorders\\,\\ often\\ with\\ severe\\ learning\\ difficulties\\,\\ mental\\ retardation\\,\\ and\\ autism\\.\\ pulmonary\\ manifestions\\ often\\ show\\ an\\ obstructive\\ pattern\\ on\\ pfts\\ with\\ interstitial\\ disease\\ with\\ cystic\\ changes\\ on\\ radiographs\\ and\\ ct\\ that\\ are\\ indistinguishable\\ from\\ lymphangioleiomyomatosis\\ \\(lam\\)\\.\\ it\\ predominantly\\ affects\\ females\\ in\\ the\\ fourth\\ decade\\,\\ often\\ presenting\\ with\\ dyspnea\\ from\\ spontaneous\\ pneumorthorax\\ in\\ up\\ to\\ a\\ third\\,\\ chronic\\ cough\\,\\ and\\/or\\ wheezing\\ with\\ chest\\ pain\\ and\\ can\\ lead\\ to\\ cyanosis\\,\\ cor\\ pulmonale\\,\\ and\\ death\\ from\\ respiratory\\ failure\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lymphangioleiomyomatosis\\:\\ 0\\.2585247239935589\ \(0\)\
\-\ pulmonary\\:\\ 0\\.22764827867263357\ \(0\)\
\-\ and\\:\\ 0\\.16292156891468945\ \(0\)\
\-\ lam\\:\\ 0\\.15823783115271414\ \(0\)\
\-\ lung\\:\\ 0\\.12621511759311482\ \(0\)\
\-\ tuberous\\:\\ 0\\.12414509871173839\ \(0\)\
\-\ shagreen\\:\\ 0\\.12264033388289482\ \(0\)\
\-\ neurocutaneous\\:\\ 0\\.11449839124445246\ \(0\)\
\-\ proteins\\:\\ 0\\.1125556209320008\ \(0\)\
\-\ pfts\\:\\ 0\\.11084197606927482\ \(0\)\
\-\ fibromas\\:\\ 0\\.10930906850423357\ \(0\)\
\-\ spontaneous\\:\\ 0\\.10832515369263702\ \(0\)\
\-\ ts\\:\\ 0\\.10792238493747904\ \(0\)\
\-\ chromosome\\:\\ 0\\.10549188743514276\ \(0\)\
\-\ in\\:\\ 0\\.10323073639467764\ \(0\)\
\-\ multiple\\:\\ 0\\.1014851027015224\ \(0\)\
\-\ cystic\\:\\ 0\\.09996860391769491\ \(0\)\
\-\ patch\\:\\ 0\\.09922435555333954\ \(0\)\
\-\ unavailable\\:\\ 0\\.091938493079775\ \(0\)\
\-\ the\\:\\ 0\\.09108141339708\ \(0\)\
\-\ familial\\:\\ 0\\.09027391796124612\ \(0\)\
\-\ involvement\\:\\ 0\\.09010352236461222\ \(0\)\
\-\ of\\:\\ 0\\.08932828408748698\ \(0\)\
\-\ including\\:\\ 0\\.08909164419650173\ \(0\)\
\-\ sclerosis\\:\\ 0\\.08867194379923365\ \(0\)\
\-\ exertion\\:\\ 0\\.08710622299136916\ \(0\)\
\-\ disease\\:\\ 0\\.08709455183161463\ \(0\)\
\-\ periventricular\\:\\ 0\\.0853224615333547\ \(0\)\
\-\ enlarged\\:\\ 0\\.08486689940746948\ \(0\)\
\-\ hormone\\:\\ 0\\.08450640660792375\ \(0\)\
\-\ death\\:\\ 0\\.08141944443143942\ \(0\)\
\-\ with\\:\\ 0\\.08125605246903955\ \(0\)\
\-\ often\\:\\ 0\\.08123010832357967\ \(0\)\
\-\ no\\:\\ 0\\.0809658528125795\ \(0\)\
\-\ her\\:\\ 0\\.07777466453197267\ \(0\)\
\-\ uterine\\:\\ 0\\.07750384698687862\ \(0\)\
\-\ interstitial\\:\\ 0\\.07523774858246066\ \(0\)\
\-\ dyspnea\\:\\ 0\\.07303501009027519\ \(0\)\
\-\ uterus\\:\\ 0\\.07279649384091859\ \(0\)\
\-\ to\\:\\ 0\\.07261894577698969\ \(0\)\
\-\ pneumothorax\\:\\ 0\\.07233088081427683\ \(0\)\
\-\ or\\:\\ 0\\.07218010471998963\ \(0\)\
\-\ lesions\\:\\ 0\\.07149636346584662\ \(0\)\
\-\ desats\\:\\ 0\\.06636252341689443\ \(0\)\
\-\ confetti\\:\\ 0\\.06636252341689443\ \(0\)\
\-\ lymphangiectasis\\:\\ 0\\.06636252341689443\ \(0\)\
\-\ fibroleiomyomatosis\\:\\ 0\\.06636252341689443\ \(0\)\
\-\ mosaicism\\:\\ 0\\.06636252341689443\ \(0\)\
\-\ tsc1\\:\\ 0\\.06636252341689443\ \(0\)\
\-\ 16p\\:\\ 0\\.06636252341689443\ \(0\)\
\-\ hamartin\\:\\ 0\\.06636252341689443\ \(0\)\
\-\ pneumorthorax\\:\\ 0\\.06636252341689443\ \(0\)\
\-\ respiratory\\:\\ 0\\.06601759680243398\ \(0\)\
\-\ from\\:\\ 0\\.06592318434691898\ \(0\)\
\-\ currently\\:\\ 0\\.06375363981816409\ \(0\)\
\-\ angiofibromas\\:\\ 0\\.06341293396348943\ \(0\)\
\-\ hypomelanotic\\:\\ 0\\.06341293396348943\ \(0\)\
\-\ subungual\\:\\ 0\\.06341293396348943\ \(0\)\
\-\ luteinizing\\:\\ 0\\.06341293396348943\ \(0\)\
\-\ lymphangiomatosis\\:\\ 0\\.06341293396348943\ \(0\)\
\-\ tsc2\\:\\ 0\\.06341293396348943\ \(0\)\
\-\ tuberin\\:\\ 0\\.06341293396348943\ \(0\)\
\-\ nevi\\:\\ 0\\.06341293396348943\ \(0\)\
\-\ manifestions\\:\\ 0\\.06341293396348943\ \(0\)\
\-\ ct\\:\\ 0\\.06319298671966525\ \(0\)\
\-\ third\\:\\ 0\\.06319278884210303\ \(0\)\
\-\ on\\:\\ 0\\.06266382981637564\ \(0\)\
\-\ ptx\\:\\ 0\\.06132016694144741\ \(0\)\
\-\ nonfatty\\:\\ 0\\.06132016694144741\ \(0\)\
\-\ lymphangiomas\\:\\ 0\\.06132016694144741\ \(0\)\
\-\ dermatologic\\:\\ 0\\.06132016694144741\ \(0\)\
\-\ lungs\\:\\ 0\\.061250018529651354\ \(0\)\
\-\ calcifications\\:\\ 0\\.06057075998813997\ \(0\)\
\-\ gingival\\:\\ 0\\.0596968907275638\ \(0\)\
\-\ analogs\\:\\ 0\\.0596968907275638\ \(0\)\
\-\ metastasizing\\:\\ 0\\.0596968907275638\ \(0\)\
\-\ leiomyomata\\:\\ 0\\.0596968907275638\ \(0\)\
\-\ pleurectomy\\:\\ 0\\.0596968907275638\ \(0\)\
\-\ autism\\:\\ 0\\.0596968907275638\ \(0\)\
\-\ pulmonale\\:\\ 0\\.0596968907275638\ \(0\)\
\-\ ox\\:\\ 0\\.05837057748804241\ \(0\)\
\-\ inhomogenous\\:\\ 0\\.05837057748804241\ \(0\)\
\-\ phakomatoses\\:\\ 0\\.05837057748804241\ \(0\)\
\-\ code\\:\\ 0\\.05837057748804241\ \(0\)\
\-\ is\\:\\ 0\\.05682099409594569\ \(0\)\
\-\ which\\:\\ 0\\.05660711420671403\ \(0\)\
\-\ genes\\:\\ 0\\.0562778104660004\ \(0\)\
\-\ hypopigmented\\:\\ 0\\.0562778104660004\ \(0\)\
\-\ learning\\:\\ 0\\.0562778104660004\ \(0\)\
\-\ cases\\:\\ 0\\.055821962104389514\ \(0\)\
\-\ functions\\:\\ 0\\.05542098803463741\ \(0\)\
\-\ bilaterally\\:\\ 0\\.055350839622841354\ \(0\)\
\-\ study\\:\\ 0\\.055350839622841354\ \(0\)\
\-\ macules\\:\\ 0\\.05465453425211678\ \(0\)\
\-\ x4\\:\\ 0\\.05465453425211678\ \(0\)\
\-\ progesterone\\:\\ 0\\.05396119246873952\ \(0\)\
\-\ pulmonologist\\:\\ 0\\.0533282210125954\ \(0\)\
\-\ sturge\\:\\ 0\\.0533282210125954\ \(0\)\
\-\ cor\\:\\ 0\\.0533282210125954\ \(0\)\
\-\ severe\\:\\ 0\\.05253862289251568\ \(0\)\
\-\ oophorectomy\\:\\ 0\\.05220683914677922\ \(0\)\
\-\ indistinguishable\\:\\ 0\\.05220683914677922\ \(0\)\
\-\ manifests\\:\\ 0\\.05170494479871179\ \(0\)\
\-\ carries\\:\\ 0\\.05123545399055338\ \(0\)\
\-\ angiomyolipomas\\:\\ 0\\.05123545399055338\ \(0\)\
\-\ hamartomas\\:\\ 0\\.05123545399055338\ \(0\)\
\-\ aside\\:\\ 0\\.050378631559190395\ \(0\)\
\-\ tried\\:\\ 0\\.050378631559190395\ \(0\)\
\-\ efficacy\\:\\ 0\\.050378631559190395\ \(0\)\
\-\ spots\\:\\ 0\\.050378631559190395\ \(0\)\
\-\ changes\\:\\ 0\\.05015795134765472\ \(0\)\
\-\ she\\:\\ 0\\.049404191945169394\ \(0\)\
\-\ lad\\:\\ 0\\.049257249693374215\ \(0\)\
\-\ hyperinflation\\:\\ 0\\.049257249693374215\ \(0\)\
\-\ chain\\:\\ 0\\.0485954679711316\ \(0\)\
\-\ telangiectasia\\:\\ 0\\.0485954679711316\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.0485954679711316\ \(0\)\
\-\ retardation\\:\\ 0\\.0485954679711316\ \(0\)\
\-\ transplantation\\:\\ 0\\.04828586453714838\ \(0\)\
\-\ weber\\:\\ 0\\.0474290421057854\ \(0\)\
\-\ difficulties\\:\\ 0\\.047164482671332206\ \(0\)\
\-\ evidence\\:\\ 0\\.0471073671560254\ \(0\)\
\-\ lymphangioma\\:\\ 0\\.04690920796396139\ \(0\)\
\-\ fibroids\\:\\ 0\\.04690920796396139\ \(0\)\
\-\ leiomyosarcoma\\:\\ 0\\.04690920796396139\ \(0\)\
\-\ mutation\\:\\ 0\\.04666258832326477\ \(0\)\
\-\ prior\\:\\ 0\\.04643513940983567\ \(0\)\
\-\ osteoblastic\\:\\ 0\\.04642405604602647\ \(0\)\
\-\ von\\:\\ 0\\.0459692465398875\ \(0\)\
\-\ ctab\\:\\ 0\\.045541206457448594\ \(0\)\
\-\ takes\\:\\ 0\\.04513695898062306\ \(0\)\
\-\ bilateral\\:\\ 0\\.044603894657087216\ \(0\)\
\-\ angiomyolipoma\\:\\ 0\\.04439019284931131\ \(0\)\
\-\ manipulation\\:\\ 0\\.04404371866897941\ \(0\)\
\-\ chest\\:\\ 0\\.04380829790052474\ \(0\)\
\-\ without\\:\\ 0\\.04377607382231734\ \(0\)\
\-\ decade\\:\\ 0\\.043712998869859764\ \(0\)\
\-\ langerhans\\:\\ 0\\.04355311149568458\ \(0\)\
\-\ connective\\:\\ 0\\.04309351135211102\ \(0\)\
\-\ cyanosis\\:\\ 0\\.04309351135211102\ \(0\)\
\-\ probable\\:\\ 0\\.042946545087339145\ \(0\)\
\-\ respectively\\:\\ 0\\.042946545087339145\ \(0\)\
\-\ wheezing\\:\\ 0\\.042946545087339145\ \(0\)\
\-\ autosomal\\:\\ 0\\.04280248923776172\ \(0\)\
\-\ syndromes\\:\\ 0\\.04266123076667735\ \(0\)\
\-\ mets\\:\\ 0\\.04266123076667735\ \(0\)\
\-\ affects\\:\\ 0\\.04252266309742928\ \(0\)\
\-\ monitor\\:\\ 0\\.04238668563033838\ \(0\)\
\-\ childhood\\:\\ 0\\.041993369158847625\ \(0\)\
\-\ yet\\:\\ 0\\.041993369158847625\ \(0\)\
\-\ may\\:\\ 0\\.04176506340375442\ \(0\)\
\-\ females\\:\\ 0\\.041742496619648385\ \(0\)\
\-\ markings\\:\\ 0\\.041620231847817754\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.041620231847817754\ \(0\)\
\-\ cv\\:\\ 0\\.0412653037645222\ \(0\)\
\-\ diminished\\:\\ 0\\.04115074103965935\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.04115074103965935\ \(0\)\
\-\ up\\:\\ 0\\.04105387239011773\ \(0\)\
\-\ but\\:\\ 0\\.041040530651114904\ \(0\)\
\-\ genetic\\:\\ 0\\.04092689006444049\ \(0\)\
\-\ definite\\:\\ 0\\.04081749578219755\ \(0\)\
\-\ hamartoma\\:\\ 0\\.04081749578219755\ \(0\)\
\-\ emphysema\\:\\ 0\\.04070972221571971\ \(0\)\
\-\ ovary\\:\\ 0\\.04060352204227958\ \(0\)\
\-\ eosinophilic\\:\\ 0\\.04039566268194538\ \(0\)\
\-\ ataxia\\:\\ 0\\.04029391860829637\ \(0\)\
\-\ every\\:\\ 0\\.04019357794599182\ \(0\)\
\-\ insufficiency\\:\\ 0\\.03999695563393414\ \(0\)\
\-\ retroperitoneal\\:\\ 0\\.03999695563393414\ \(0\)\
\-\ fatty\\:\\ 0\\.039437096176933376\ \(0\)\
\-\ pulse\\:\\ 0\\.03917253674248018\ \(0\)\
\-\ also\\:\\ 0\\.03903787345407785\ \(0\)\
\-\ relief\\:\\ 0\\.03891726203510938\ \(0\)\
\-\ dominant\\:\\ 0\\.03883412304239847\ \(0\)\
\-\ cns\\:\\ 0\\.03875192349343931\ \(0\)\
\-\ rrr\\:\\ 0\\.03867064239441276\ \(0\)\
\-\ abd\\:\\ 0\\.038590259447456164\ \(0\)\
\-\ obstructive\\:\\ 0\\.038590259447456164\ \(0\)\
\-\ iliac\\:\\ 0\\.03820115158625435\ \(0\)\
\-\ progression\\:\\ 0\\.03805115487666401\ \(0\)\
\-\ episodes\\:\\ 0\\.037904188611892126\ \(0\)\
\-\ granuloma\\:\\ 0\\.03754926052859657\ \(0\)\
\-\ replacement\\:\\ 0\\.037277281835283525\ \(0\)\
\-\ fourth\\:\\ 0\\.03721084682851486\ \(0\)\
\-\ heent\\:\\ 0\\.03707976972043817\ \(0\)\
\-\ lead\\:\\ 0\\.03695101268340061\ \(0\)\
\-\ vitals\\:\\ 0\\.036638750896498526\ \(0\)\
\-\ disorders\\:\\ 0\\.036638750896498526\ \(0\)\
\-\ prognosis\\:\\ 0\\.036517505045137594\ \(0\)\
\-\ bodies\\:\\ 0\\.03633934309513244\ \(0\)\
\-\ predominantly\\:\\ 0\\.03633934309513244\ \(0\)\
\-\ mental\\:\\ 0\\.03616544040713841\ \(0\)\
\-\ scattered\\:\\ 0\\.036108384564212344\ \(0\)\
\-\ that\\:\\ 0\\.03601616772197541\ \(0\)\
\-\ problems\\:\\ 0\\.03599559807734672\ \(0\)\
\-\ kidneys\\:\\ 0\\.035721052941007754\ \(0\)\
\-\ node\\:\\ 0\\.0356673657402727\ \(0\)\
\-\ structure\\:\\ 0\\.03545649350655456\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.03515122147054481\ \(0\)\
\-\ disorder\\:\\ 0\\.035101565423259005\ \(0\)\
\-\ numerous\\:\\ 0\\.03505224602972903\ \(0\)\
\-\ poor\\:\\ 0\\.03500325875584582\ \(0\)\
\-\ medications\\:\\ 0\\.0348105433089097\ \(0\)\
\-\ fibrosis\\:\\ 0\\.034763151723177295\ \(0\)\
\-\ represent\\:\\ 0\\.034530717168577266\ \(0\)\
\-\ seizure\\:\\ 0\\.034530717168577266\ \(0\)\
\-\ 36\\:\\ 0\\.03434997289755458\ \(0\)\
\-\ either\\:\\ 0\\.03430547989841728\ \(0\)\
\-\ facial\\:\\ 0\\.0342173020590122\ \(0\)\
\-\ continued\\:\\ 0\\.03400142322999561\ \(0\)\
\-\ foci\\:\\ 0\\.03391683410617624\ \(0\)\
\-\ seizures\\:\\ 0\\.03387490555966236\ \(0\)\
\-\ last\\:\\ 0\\.03375055069079637\ \(0\)\
\-\ features\\:\\ 0\\.033389753641727436\ \(0\)\
\-\ as\\:\\ 0\\.03334152801976824\ \(0\)\
\-\ drainage\\:\\ 0\\.033234969447474984\ \(0\)\
\-\ cxr\\:\\ 0\\.03319678257405649\ \(0\)\
\-\ family\\:\\ 0\\.03264680418557224\ \(0\)\
\-\ presenting\\:\\ 0\\.032506904053149564\ \(0\)\
\-\ considered\\:\\ 0\\.032335729504201764\ \(0\)\
\-\ lymph\\:\\ 0\\.03226837177591126\ \(0\)\
\-\ reports\\:\\ 0\\.03226837177591126\ \(0\)\
\-\ sounds\\:\\ 0\\.03203741324499115\ \(0\)\
\-\ complex\\:\\ 0\\.0319727498620527\ \(0\)\
\-\ partial\\:\\ 0\\.0319727498620527\ \(0\)\
\-\ symptomatic\\:\\ 0\\.03190865620795359\ \(0\)\
\-\ progressive\\:\\ 0\\.03178213853762035\ \(0\)\
\-\ an\\:\\ 0\\.0317365249062859\ \(0\)\
\-\ history\\:\\ 0\\.03170841056833361\ \(0\)\
\-\ vertebral\\:\\ 0\\.03168867366286126\ \(0\)\
\-\ vs\\:\\ 0\\.03165778366875436\ \(0\)\
\-\ extremities\\:\\ 0\\.03153551889692373\ \(0\)\
\-\ failure\\:\\ 0\\.03150527110830666\ \(0\)\
\-\ are\\:\\ 0\\.0314923471358657\ \(0\)\
\-\ unknown\\:\\ 0\\.031445150248081366\ \(0\)\
\-\ rare\\:\\ 0\\.03132637891292958\ \(0\)\
\-\ pattern\\:\\ 0\\.03098127471050785\ \(0\)\
\-\ cough\\:\\ 0\\.03098127471050785\ \(0\)\
\-\ skin\\:\\ 0\\.030869784671089428\ \(0\)\
\-\ effusion\\:\\ 0\\.030814673932651637\ \(0\)\
\-\ defect\\:\\ 0\\.030440164188322436\ \(0\)\
\-\ breath\\:\\ 0\\.03041413703110754\ \(0\)\
\-\ since\\:\\ 0\\.030059208947811986\ \(0\)\
\-\ very\\:\\ 0\\.029768186833462686\ \(0\)\
\-\ pelvis\\:\\ 0\\.029023160408647698\ \(0\)\
\-\ benign\\:\\ 0\\.02850554649656214\ \(0\)\
\-\ although\\:\\ 0\\.02825027178919133\ \(0\)\
\-\ back\\:\\ 0\\.027675419811420677\ \(0\)\
\-\ radiographs\\:\\ 0\\.02691431695424725\ \(0\)\
\-\ adjacent\\:\\ 0\\.02689827597160304\ \(0\)\
\-\ any\\:\\ 0\\.02681859738005769\ \(0\)\
\-\ will\\:\\ 0\\.026708493486276217\ \(0\)\
\-\ show\\:\\ 0\\.02634316571188636\ \(0\)\
\-\ usually\\:\\ 0\\.026123814942614614\ \(0\)\
\-\ diffuse\\:\\ 0\\.026023671613318304\ \(0\)\
\-\ treated\\:\\ 0\\.02584127136381893\ \(0\)\
\-\ demonstrated\\:\\ 0\\.025502857663737215\ \(0\)\
\-\ years\\:\\ 0\\.025437023886993402\ \(0\)\
\-\ for\\:\\ 0\\.02515476351789396\ \(0\)\
\-\ syndrome\\:\\ 0\\.025016852472364973\ \(0\)\
\-\ two\\:\\ 0\\.02464309660067136\ \(0\)\
\-\ chronic\\:\\ 0\\.0246313539303548\ \(0\)\
\-\ secondary\\:\\ 0\\.024596239223324098\ \(0\)\
\-\ been\\:\\ 0\\.024176544424215827\ \(0\)\
\-\ months\\:\\ 0\\.02415453356723727\ \(0\)\
\-\ cyst\\:\\ 0\\.023938012146977532\ \(0\)\
\-\ enhancement\\:\\ 0\\.02388487398023003\ \(0\)\
\-\ due\\:\\ 0\\.023853176402054924\ \(0\)\
\-\ cell\\:\\ 0\\.023738119496784865\ \(0\)\
\-\ these\\:\\ 0\\.023433273943251703\ \(0\)\
\-\ increased\\:\\ 0\\.02243953218956498\ \(0\)\
\-\ follow\\:\\ 0\\.02237041449448786\ \(0\)\
\-\ surgery\\:\\ 0\\.02231047056640384\ \(0\)\
\-\ can\\:\\ 0\\.021776240904610673\ \(0\)\
\-\ tissue\\:\\ 0\\.02176832083558499\ \(0\)\
\-\ mri\\:\\ 0\\.021300809236439344\ \(0\)\
\-\ it\\:\\ 0\\.021241665962035545\ \(0\)\
\-\ have\\:\\ 0\\.02072996098175761\ \(0\)\
\-\ female\\:\\ 0\\.020024152044203762\ \(0\)\
\-\ treatment\\:\\ 0\\.019767159404912932\ \(0\)\
\-\ within\\:\\ 0\\.019112177091790257\ \(0\)\
\-\ has\\:\\ 0\\.018954559496857367\ \(0\)\
\-\ be\\:\\ 0\\.016833619781915877\ \(0\)\
\-\ there\\:\\ 0\\.016511474393373398\ \(0\)\
\-\ pain\\:\\ 0\\.01484910597048375\ \(0\)\
\-\ left\\:\\ 0\\.014155486207676905\ \(0\)\
\-\ year\\:\\ 0\\.012788517249737539\ \(0\)\
